This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Curagen (CRGN) was one of few winners of Tuesday's session. Earlier, BWS Financial upgraded the stock to strong buy from buy. Curagen was adding 44 cents, or 12.4%, to $4.

Oscient Pharmaceuticals (OSCI) was also higher after posting a narrower-than-expected fourth-quarter loss, thanks to sales of the company's Antara cardiovascular drug. Shares of Oscient were up 15 cents, or 3%, to $5.10.

Threshold (THLD - Get Report) plummeted 57.5% after the company said late Monday that a phase III clinical trial of its drug glufosfamide failed to show the ability to extend the lives of patients with advanced pancreatic cancer. Threshold was down $2.06 to $1.52.

Drugmaker Teva Pharmaceutical (TEVA - Get Report) was lower after a study of the multiple sclerosis drug Copaxone had disappointing results. Teva was losing $2, or 5.3%, to $35.51.

Among other healthcare stocks, Chad Therapeutics (CTU) was gaining 7 cents, or 4.1%, to $1.77; Celgene (CELG - Get Report) was losing $4.05, or 7.1%, to $53.17; Forest Laboratories (FRX) sank $2.57, or 4.7%, to $52.55; and Amgen (AMGN - Get Report) was down $1.95, or 3%, to $64.25.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
AMGN $155.89 0.00%
CELG $124.04 0.00%
THLD $4.34 0.00%
TEVA $65.03 0.00%
AAPL $113.29 0.00%


Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs